Document Type : Systematic Review

Authors

1 Department of Pathology, Tehran University of medical sciences, Tehran,Iran

2 Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background & Objective: The most frequent type of cancer found in the endocrine system is thyroid carcinoma. Among well-differentiated thyroid malignancies, the most commonly occurring type is identified as papillary thyroid carcinoma (PTC), which makes up 70-90% of the cases. A subtype of PTC is papillary thyroid microcarcinoma (PTMC), which includes tumors smaller than 10 mm in diameter. Due to the advancements in diagnostic techniques, the incidence of this type of cancer is on the rise. In this study, we aimed to analyze the factors worsening the PTMC prognosis.
Methods: In the first step, we searched various databases for the factors affecting this tumor. The relevant articles were collected and different outcomes of this tumor and its associated factors which were studied in more than one article, were classified. Finally, we conducted a meta-analysis of these outcomes and their related factors.
Results: In the meta-analysis, a significantly association was found between the following factors: recurrence with gender (P<0.001) lymph node metastasis (LNM) (P= 0.003), and extrathyroidal invasion (P<0.001); lymph node metastasis with extrathyroidal invasion (P<0.001), and multifocality (P<0.001); central lymph node metastasis (CLNM) with gender (P=0.001), tumor size (P<0.001), extracapsular invasion (P<0.001), lateral cervical lymph node metastasis (P<0.001), and extrathyroidal invasion (P<0.001); lymph node metastasis resulted in poor outcomes (P<0.001); and finally tumor size with BRAFV600E mutation (P<0.001).
Conclusion: In conclusion, it is essential to note that greater awareness and understanding of this tumor characteristics and special and separate attention to PTMC can significantly improve the society overall health.

Keywords

Main Subjects

  1. Goldman L, Schafer AI. Goldman-Cecil Medicine: Elsevier/Saunders; 2016.
  2. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2): McGraw-Hill Education; 2018.
  3. Lombardi CP, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34(6):1214-21. [DOI:10.1007/s00268-009-0375-x] [PMID]
  4. Yang GC, LiVolsi VA, Baloch ZW. Thyroid microcarcinoma: fine-needle aspiration diagnosis and histologic follow-up. Int J Surg Pathol. 2002;10(2):133-9. [DOI:10.1177/106689690201000206] [PMID]
  5. Wang Y, Li L, Wang Y-XJ, Feng X-L, Zhao F, Zou S-M, et al. Ultrasound findings of papillary thyroid microcarcinoma: a review of 113 consecutive cases with histopathologic correlation. Ultrasound Med 2012;38(10): 1681-8. [PMID]   [DOI:10.1016/j.ultrasmedbio.2012.05.019]
  6. Moon HJ, Son E, Kim E-K, Yoon JH, Kwak JY. The diagnostic values of ultrasound and ultrasound-guided fine needle aspiration in subcentimeter-sized thyroid nodules. Ann Surg Oncol. 2012;19:52-9. [DOI:10.1245/s10434-011-1813-1] [PMID]
  7. Page C, Biet A, Boute P, Cuvelier P, Strunski V. 'Aggressive papillary'thyroid microcarcinoma. Eur Arch Oto-Rhino-Laryngol. 2009;266:1959-63. [DOI:10.1007/s00405-009-0952-5] [PMID]
  8. Novosel T, Ritter HE, Gupta M, Harvey A, Mitchell J, Berber E, et al. Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. Surgery. 2009;146(6):1081-9. [DOI:10.1016/j.surg.2009.09.008] [PMID]
  9. Goldust M, Sokouti M, Montazeri V, Fakhrjoo A, Samankan S. A clinical epidemiologic study of thyroid carcinoma in patients under 25 years old in Tabriz, Iran (1995-2010). JPMA J Pak Med Assoc. 2012;62(11):1265-8.
  10. Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey III TJ. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid. 2009;19(5):473-7. [DOI:10.1089/thy.2008.0185] [PMID]
  11. Törüner FB, Altinova AE, Taneri F, Aktürk M, Atasever T, Poyraz A. Management of Papillary Thyroid Microcarcinomas: Our Clinical Experience. Turk Jem. 2006;3:53-6.
  12. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF V600E mutational status of 977 cases. Ann Surg Oncol. 2013;20:2266-73. [DOI:10.1245/s10434-012-2851-z] [PMID]
  13. Ardito G, Revelli L, Giustozzi E, Salvatori M, Fadda G, Ardito F, et al. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med. 2013;38(1): 25-8. [DOI:10.1097/RLU.0b013e318279bc65] [PMID]
  14. Creach KM, Siegel BA, Nussenbaum B, Grigsby PW. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. Int Sch Res Notices. 2012;2012. [DOI:10.5402/2012/816386] [PMID]
  15. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19(7):707-16. [DOI:10.1089/thy.2008.0270] [PMID]
  16. Kuo S-F, Chao T-C, Chang H-Y, Hsueh C, Yang C-H, Lin J-D. Prognostic evaluation of patients with multicentric papillary thyroid microcarcinoma. J Formos Med Assoc. 2011;110(8):511-7. [DOI:10.1016/S0929-6646(11)60077-6] [PMID]
  17. Min HS, Choe G, Kim S-W, Park YJ, Park DJ, Youn Y-K, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol. 2008;21(6):748-55. [DOI:10.1038/modpathol.2008.51] [PMID]
  18. Lin K-L, Wang O-C, Zhang X-H, Dai X-X, Hu X-Q, Qu J-M. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17:3294-300. [DOI:10.1245/s10434-010-1129-6] [PMID]
  19. Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2013;20:746-52. [DOI:10.1245/s10434-012-2654-2] [PMID]
  20. Yun M, Noh T-W, Cho A, Choi Y-J, Hong S-W, Park C-S, et al. Visually discernible [18F] fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. The J Clin Endocrinol Metab. 2010;95(7):3182-8. [DOI:10.1210/jc.2009-2091] [PMID]
  21. Moon HJ, Kim E-K, Yoon JH, Kwak JY. Clinical implication of elastography as a prognostic factor of papillary thyroid microcarcinoma. Ann Surg Oncol. 2012;19:2279-87. [DOI:10.1245/s10434-011-2212-3] [PMID]
  22. Lee NS, Bae JS, Jeong S-R, Jung CK, Lim DJ, Park WC, et al. Risk factors of lymph node metastasis in papillary thyroid microcarcinoma. J Korean Surg Soc. 2010;78(2):82-6. [DOI:10.4174/jkss.2010.78.2.82]
  23. Zhou Y-L, Gao E-l, Zhang W, Yang H, Guo G-L, Zhang X-H, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: a retrospective study. World J Surg Oncol. 2012;10:1-6. [DOI:10.1186/1477-7819-10-67] [PMID]
  24. Kim B-Y, Jung C-H, Kim J-W, Lee S-W, Kim C-H, Kang S-K, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J. 2012;53(5):924-30. [DOI:10.3349/ymj.2012.53.5.924] [PMID]
  25. Kim K-E, Kim E-K, Yoon JH, Han KH, Moon HJ, Kwak JY. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2013;37:385-91. [DOI:10.1007/s00268-012-1826-3] [PMID]
  26. Roh J-L, Kim J-M, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol. 2008;15:2482-6. [DOI:10.1245/s10434-008-0044-6] [PMID]
  27. Caliskan M, Park JH, Jeong JS, Lee C-R, Park SK, Kang S-W, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J. 2012;59(4):305-11. [DOI:10.1507/endocrj.EJ11-0366] [PMID]
  28. Kim YW, Wang SG, Lee JC, Lee BJ, Lee JW, Kim YK, et al. Clinically Related Factors and Features of Central Compartment Neck Lymph Nodes in Thyroid Micropapillary Carcinoma. Korean J Otorhinolaryngol Head Neck Surg. 2009;52(3):232-6. [DOI:10.3342/kjorl-hns.2009.52.3.232]
  29. Tzvetov G, Hirsch D, Shraga-Slutzky I, Weinstein R, Manistersky Y, Kalmanovich R, et al. Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. Thyroid. 2009;19(5):487-94. [DOI:10.1089/thy.2008.0228] [PMID]
  30. Giordano D, Gradoni P, Oretti G, Molina E, Ferri T. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol. 2010;35(2):118-24. [DOI:10.1111/j.1749-4486.2010.02085.x] [PMID]
  31. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253(3):854-60. [DOI:10.1148/radiol.2533090471] [PMID]
  32. Tzvetov G, Hirsch D, Shraga-Slutzky I, Weinstein R, Manistersky Y, Kalmanovich R, et al. Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. Thyroid. 2009;19(5):487-94. [DOI:10.1089/thy.2008.0228] [PMID]
  33. Giordano D, Gradoni P, Oretti G, Molina E, Ferri T. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol. 2010;35(2):118-24. [DOI:10.1111/j.1749-4486.2010.02085.x] [PMID]
  34. Kwak JY, Kim E-K, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253 (3):854-60. [DOI:10.1148/radiol.2533090471] [PMID]
  35. Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, et al. BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol. 2013;121(6):291-7. [DOI:10.1002/cncy.21258] [PMID]
  36. Sethom A, Riahi I, Riahi K, Akkari K, Benzarti S, Miled I, et al. [Management of thyroid microcarcinoma. Report of 13 cases]. Tunisie Méd. 2011;89:23-5.
  37. So YK, Kim M-J, Kim S, Son Y-I. Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location. Int J Surg. 2018;50:94-103. [DOI:10.1016/j.ijsu.2017.12.029] [PMID]
  38. Kim TY, Hong SJ, Kim JM, Gu Kim W, Gong G, Ryu JS, et al. Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer. 2008;8:1-11. [DOI:10.1186/1471-2407-8-296] [PMID] []
  39. Kwak JY, Kim E-K, Kim MJ, Son EJ, Chung WY, Park CS, et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol. 2009;16:1348-55. [DOI:10.1245/s10434-009-0384-x] [PMID]
  40. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27-34. [DOI:10.1089/thy.2013.0367] [PMID]